- 341
- 74 570
San Antonio Breast Cancer Symposium
United States
เข้าร่วมเมื่อ 28 เม.ย. 2022
Since 1977, the Symposium’s mission has been to provide state-of-the-art information on breast cancer research. From a one-day regional conference, the Symposium has grown to a five-day program attended by a broad international audience of academic and private researchers and physicians from over 90 countries.
The Symposium aims to achieve a balance of clinical, translational, and basic research, providing a forum for interaction, communication, and education for a broad spectrum of researchers, health professionals, and those with a special interest in breast cancer.
The Symposium aims to achieve a balance of clinical, translational, and basic research, providing a forum for interaction, communication, and education for a broad spectrum of researchers, health professionals, and those with a special interest in breast cancer.
SABCS Snippets: The US FDA Approval of Ribociclib
In this SABCS Snippets, Dr. Virginia Kaklamani, co-director of the San Antonio Breast Cancer Symposium, talks with Dr. Lisa Carey of the UNC Lineberger Comprehensive Cancer Center about the September 2024 FDA approval of ribociclib for adults with HR-positive, HER2-negative early-stage, high-risk breast cancer.
มุมมอง: 235
วีดีโอ
SABCS Snippets: After ASCO 2024
มุมมอง 4385 หลายเดือนก่อน
Dr. Virginia Kaklamani, MD, of UT Health San Antonio and SABCS Co-Director, discusses the clinical implications of several studies presented at ASCO 2024 with Dr. William J. Gradishar of Northwestern University, Dr. Heather McArthur of UT Southwestern, and Dr. Aditya Bardia of UCLA.
SABCS Snippets: KEYNOTE-522 Phase 3 Results
มุมมอง 3795 หลายเดือนก่อน
Sara M. Tolaney, MD, MPH, of the Dana-Farber Cancer Institute, and Kate Lathrop, MD, SABCS Program Director, discuss the recent results of phase 3 KEYNOTE-522 trial investigating pembrolizumab in combination with chemotherapy as pre-operative treatment and then continuing as a single agent treatment after surgery for patients with high-risk early-stage triple-negative breast cancer. Previous re...
SABCS Snippets: DESTINY-Breast06 Phase III Trial
มุมมอง 5736 หลายเดือนก่อน
Aditya Bardia, MD, MPH, a breast medical oncologist at the UCLA Health Jonsson Comprehensive Cancer Center, and Virginia Kaklamani, MD, SABCS co-director and the leader of the breast medical oncology program at Mays Cancer Center at UT Health San Antonio, discuss the results of the phase III DESTINY-Breast06 trial, in which trastuzumab deruxtecan (Enhertu) demonstrated improvement in progressio...
Poster Spotlight: Breast Cancer Prevention
มุมมอง 2397 หลายเดือนก่อน
Dr. Neil M. Iyengar moderates this session on breast cancer prevention with discussions of the scientific abstracts by Drs. Pamela J. Goodwin and Seema Khan. PS07-01 Exemestane and breast cancer prevention: how low can we go? Drug and biomarker tissue levels in a randomized presurgical trial on exemestane alternative dosing regimen. Davide Serrano PS07-02 Benign breast disease and microcalcific...
Poster Spotlight: Prognostic and Predictive Uses of Cell Free DNA
มุมมอง 1737 หลายเดือนก่อน
This poster session moderated by Dr. Maggie Chon U Cheang reviews the results of cell free DNA anaylsis across a range of clinical trials. Drs. David Cescon and Ben Park provide summary discussions of the posters. PS06-01 Results from a pilot study exploring ctDNA detection using a tumor-informed assay in the monarchE trial of adjuvant abemaciclib with endocrine therapy in HR , HER2-, node-posi...
Poster Spotlight: Shining a New Light on Breast Cancer
มุมมอง 1357 หลายเดือนก่อน
Innovative session moderated by Dr. David Mankoff focused on advances in molecular and functional imaging in breast cancer. Discussion provided by Drs. Farrokh Dehdashti and Amy Fowler. PS05-01 Accuracy and safety of fibroblast activation protein inhibitor (FAPI) PET/CT in diagnosis of axillary lymph node metastasis in early breast cancer patients: a prospective cohort study (PFB-01&02 study). ...
Poster Spotlight: Gaps in the Timing, Treatment Selection, and Supportive Services for Cancer Care
มุมมอง 1477 หลายเดือนก่อน
Poster session moderated by Dr. Malinda T. West addresses the impact on patients from delays and barriers to providing care. Discussions lead by Drs. Sarah Schellhorn and Claire C. Conley. PS04-01 Clinical impact of timing of systemic therapy in patients with early triple negative breast cancer. Stephan Seitz PS04-02 BRCA testing and PARP inhibitor utilization in real-world HER2-negative metast...
Poster Spotlight Session: Insights from Single Cell, Spatial, and Artificial Intelligence Approach
มุมมอง 1307 หลายเดือนก่อน
Dr. Glenn Broeckx, Bsc, MD moderates this session focused on novel technologies advancing the field of breast cancer research with discussants Drs. Ratna K. Vadlamudi, PhD and Eugene Douglass, PhD. (PS03-01) Single cell analysis of paired lymph nodes and primary tumors in breast cancer patients: Marit Otterlei Fjørtoft (PS03-02) Single-cell metabolic profiling uncovers new precision immunothera...
Poster Spotlight: Improving QOL and Care Delivery for the Breast Cancer Patient
มุมมอง 1107 หลายเดือนก่อน
Dr. Anne Blaes moderates this session highlighting improve research on improving quality of life and care delivery for breast cancer patients with discussants Drs,. Don S. Dizon and Lindsay L. Peterson, MD, MSCR. (PS02-01) Efficacy, safety, and quality of life with ribociclib endocrine therapy in elderly patients with HR /HER2- advanced breast cancer across the MONALEESA-2, -3, and -7 trials: L...
Poster Spotlight Session: Less is More.
มุมมอง 2547 หลายเดือนก่อน
Dr Tari A. King, MD moderates a poster session focused on "Minimizing Surgical Treatment in Patients with Early Stage Breast Cancer" and discussions by Melissa Pilewskie, MD, FACS and (PS01-01) Feasibility and oncological safety of targeted axillary dissection or sentinel lymph node biopsy in patients with clinically node-positive disease after neoadjuvant chemotherapy in the prospective MF-180...
Year in Review
มุมมอง 3417 หลายเดือนก่อน
Breast Cancer experts review the research highlights from 2023. This is a must view session! Basic Science: Heide L. Ford, PhD Translational: Jennifer K. Richer, PhD Early Breast Cancer: Ann Partridge, MD, MPH Advanced Breast Cancer: Mariana Chavez Mac Gregor, MD, MSC, FASCO
View from the Trenches: What to do Monday Morning
มุมมอง 1797 หลายเดือนก่อน
This is a lively conversation and debate about the impact of the scientific presentations at SABCS 2023 and what provides will be doing differently in the clinic on Monday morning. The session is moderated by Dr. Sara Tolaney, MD, MPH Panel inclues: William E. Barlow PhD, Javier Cortes Castan MD PhD, Lesley K. Glenn BS, Heather McArthur MD MPH, Joyce O'Shaughnessy MD, Alastair M. Thompson MD, R...
Translational Controversies
มุมมอง 947 หลายเดือนก่อน
Dr. Komal Jhaveri, MD, FACP moderates this engaging session on translational controversies that directly influence patient care decisions: 1. Baby-TAM Impact on disease progression: Jack M. Cuzick, CBE, PhD, FRS, FMedSci, FRCP (hon) and Per F. Hall, MD, PhD 2.When to do a window trial: Mitchell Dowsett, PhD and Sara Hurvitz, MD, FACP 3. Are we sequencing too late? Charles Perou, PhD and Christo...
State of the Art: Targeting Mutant ER
มุมมอง 977 หลายเดือนก่อน
Dr. Aditya Bardia, MD, MPH moderates this translational session on estrogen receptor mutations and how to best target mutations for optimal treatment outcomes: 1. SERMs versus SERDs for targeting ESR1 mutations: Geoffrey L. Greene, PhD 2. Tracking mutant ER using ctDNA: François-Clément Bidard, MD, PhD 3. The Future of Oral SERDs: Erika P. Hamilton, MD
State of the Art: Implications of Senescence for Breast Cancer Biology and Treatment
มุมมอง 3817 หลายเดือนก่อน
State of the Art: Implications of Senescence for Breast Cancer Biology and Treatment
State of the Art: Immunotherapy Purpose, Resistance, and Toxicity
มุมมอง 3377 หลายเดือนก่อน
State of the Art: Immunotherapy Purpose, Resistance, and Toxicity
Special Session: Social Determinants of Health Impact on Cancer Care
มุมมอง 1007 หลายเดือนก่อน
Special Session: Social Determinants of Health Impact on Cancer Care
Special Session: Prevention, Early Detection, and Interception
มุมมอง 847 หลายเดือนก่อน
Special Session: Prevention, Early Detection, and Interception
Special Session: New Drug Approvals for Metastatic Breast Cancer
มุมมอง 4727 หลายเดือนก่อน
Special Session: New Drug Approvals for Metastatic Breast Cancer
Rapid fire Session 2: Mini Oral Presentations
มุมมอง 4567 หลายเดือนก่อน
Rapid fire Session 2: Mini Oral Presentations
Rapid fire Session 1: Mini Oral Presentations
มุมมอง 2427 หลายเดือนก่อน
Rapid fire Session 1: Mini Oral Presentations
Plenary Lecture Dr. Melinda Telli, MD: Recent Advances in Triple Negative Breast Cancer
มุมมอง 6417 หลายเดือนก่อน
Plenary Lecture Dr. Melinda Telli, MD: Recent Advances in Triple Negative Breast Cancer
Plenary Lecture Dr. Charles Swanton MD, PhD: Breast Cancer Evolution, Immune Evasion & Metastasis
มุมมอง 5867 หลายเดือนก่อน
Plenary Lecture Dr. Charles Swanton MD, PhD: Breast Cancer Evolution, Immune Evasion & Metastasis
Materials and Methods: Basic Science to Breast Oncology Workshop
มุมมอง 1517 หลายเดือนก่อน
Materials and Methods: Basic Science to Breast Oncology Workshop
McGuire Award Lecture: Jack M. Cuzick, CBE, PhD
มุมมอง 677 หลายเดือนก่อน
McGuire Award Lecture: Jack M. Cuzick, CBE, PhD
Debate Anthracyclines…To give or not to give
มุมมอง 4637 หลายเดือนก่อน
Debate Anthracyclines…To give or not to give
Clinical Workshop:Tumor Agnostic Approaches to Care
มุมมอง 1037 หลายเดือนก่อน
Clinical Workshop:Tumor Agnostic Approaches to Care
🙏🏼🙏🏼🙏🏼
Thank you for this. We need more trials addressing ILC treatments.
A very reasonable presentation. It is expected that detections would be lower during a period when these were shut down, and a restoration of levels once screening was resumed. Nice to see that while there was a slight increase following the resumption of screening, probably due to missed screening opportunities during the shut down, it wasn't crazy. I would very much like to see the subsequent data from June 2021 to June 2024. Covid-19 did not appear to impact on breast cancer. I would be curious to see what impact, if any, the vaccines had on this. I would suspect little impact from vector based vaccines, but I am curious about the impact of mRNA vaccines given the more recent disclosure that commercial versions included leftover strands of DNA (fragmented) from the production process. These were cleaned up for the trials, but shear volume of production seemed to make this less feasible. I would like to know what impact that had, if any. The early part of the roll-out also seemed to be pretty quiet as well (2020-2021).
Have you done the same analysis to see how the Covid vaccines effected breast cancer. I am hearing a lot about 'turbo' cancers since the vaccine rollouts
Thank you for curing me from breast cancer virus with your herbal remedies, you have really proven yourself to be a real doctor, I will definitely spread this all over the world, I am totally free from Breast cancer virus #dremovon on TH-cam..🙏🙏
Ok, after listening to this video I realized maybe I was not the target audience. I just wanted to know what the percentage of getting uterine cancer while on tamoxifen?
More on Enobosarm asap please!
Please join elacestrant(Orserdu)for Metavivors if you are going on this medication. We are a private group.
I wish someone would focus on mTNBC patients.
Are there any immunotherapies available for mTNBC patients with a positive PD-L1 of 6?
Are you going to be posting any TH-cam videos on TNBC?
Very interesting and informative presentation. Great job Dr. Karadal-Ferrena!
Wow! Amazing presentation by the talented and brilliant young Dr. Karadal-Ferrena!!
🙏
P R O M O S M